IVERMECTIN
Off-Label / Experimental / Investigational Uses & Cancer Dosage Guide

PHARMACYIN USA

⚠️ Off-Label / Experimental / Investigational Uses

Disease	Dosage per kg	Notes
COVID-19	0.2–0.4 mg/kg	Not approved, but used in some protocols early in pandemic
Malaria (Vector Control)	0.2 mg/kg	Not a cure — used in mosquito population control
Zika Virus	0.2–0.4 mg/kg	In vitro antiviral effect only
Yellow Fever	0.2–0.4 mg/kg	Limited research
Dengue	0.2 mg/kg	Investigated for viral reduction and mosquito control
West Nile Virus	0.2 mg/kg	Animal research only
Tuberculosis (Drug-Resistant)	0.2–0.4 mg/kg	In vitro synergy with TB antibiotics
Neurocysticercosis (Seizure cause	0.2 mg/kg	Adjunct to Albendazole
Leishmaniasis	0.2–0.4 mg/kg	Under investigation

🎗️ Cancer (Experimental / Integrative Use)

Disease	Dosage per kg	Notes
Lung Cancer (NSCLC, SCLC)	0.2–0.4 mg/kg daily	Shown to inhibit tumor growth & induce apoptosis in studies
Colon / Colorectal Cancer	0.2–0.4 mg/kg daily	Disrupts WNT/β-catenin & PI3K/Akt pathways
Gastric (Stomach) Cancer	0.2–0.4 mg/kg daily	Anecdotal remission cases reported
Breast Cancer	0.2–0.4 mg/kg daily	Inhibits PAK1 & cell migration
Liver Cancer	0.2–0.4 mg/kg daily	Anti-proliferative effect in vitro
Pancreatic Cancer	0.2–0.4 mg/kg daily	Blocks angiogenesis, early evidence
Brain Tumors / Glioblastoma	0.2–0.4 mg/kg daily	Crosses blood-brain barrier; early research only
Prostate Cancer	0.2–0.4 mg/kg daily	Inhibits androgen receptor signaling
Leukemia / Lymphoma	0.2–0.4 mg/kg daily	Targets cancer stem-like cells
Melanoma / Skin Cancer	0.2–0.4 mg/kg daily	Topical & oral experimental use
Ovarian Cancer	0.2–0.4 mg/kg daily	Some lab-based activity
Esophageal Cancer	0.2–0.4 mg/kg daily	Anecdotal reports; not widely studied